{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:48:25Z","timestamp":1785750505547,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16117-9","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:53:29Z","timestamp":1779965609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematologic toxicity of immune checkpoint inhibitors: real-world burden and risk profiles from a five-year cohort from the Middle East"],"prefix":"10.1186","volume":"26","author":[{"given":"Ali","family":"Awada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Hammoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Charbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"El Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali ElHadi","family":"Zreik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Kreidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"12","key":"16117_CR1","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024;35(12):1191\u20139.","journal-title":"Ann Oncol"},{"issue":"14","key":"16117_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"4","key":"16117_CR3","doi-asserted-by":"publisher","first-page":"104506","DOI":"10.1016\/j.esmoop.2025.104506","volume":"10","author":"S Gupta","year":"2025","unstructured":"Gupta S, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients. ESMO Open. 2025;10(4):104506.","journal-title":"ESMO Open"},{"issue":"2","key":"16117_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"36","key":"16117_CR5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16117_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"1","key":"16117_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2021","unstructured":"Muntyanu A, et al. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management. J Cutan Med Surg. 2021;25(1):59\u201376.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"16117_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87.","journal-title":"BMC Med"},{"issue":"1","key":"16117_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10238-025-01688-x","volume":"25","author":"X Han","year":"2025","unstructured":"Han X, et al. Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials. Clin Exp Med. 2025;25(1):157.","journal-title":"Clin Exp Med"},{"issue":"2","key":"16117_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, et al. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest. 2017;152(2):271\u201381.","journal-title":"Chest"},{"issue":"12","key":"16117_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"5","key":"16117_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, et al. Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist. 2019;24(5):584\u20138.","journal-title":"Oncologist"},{"issue":"1","key":"16117_CR13","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6(1):e48\u201357.","journal-title":"Lancet Haematol"},{"issue":"1","key":"16117_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","volume":"101","author":"P Ghanem","year":"2022","unstructured":"Ghanem P, et al. Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review. Ann Hematol. 2022;101(1):1\u201310.","journal-title":"Ann Hematol"},{"issue":"3","key":"16117_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1759-7714.13281","volume":"11","author":"J Zhuang","year":"2020","unstructured":"Zhuang J, et al. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thorac Cancer. 2020;11(3):799\u2013804.","journal-title":"Thorac Cancer"},{"issue":"5","key":"16117_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ajh.25448","volume":"94","author":"RK Leaf","year":"2019","unstructured":"Leaf RK, et al. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019;94(5):563\u201374.","journal-title":"Am J Hematol"},{"key":"16117_CR17","doi-asserted-by":"publisher","first-page":"765608","DOI":"10.3389\/fonc.2021.765608","volume":"11","author":"A Zaremba","year":"2021","unstructured":"Zaremba A, et al. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. Front Oncol. 2021;11:765608.","journal-title":"Front Oncol"},{"key":"16117_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","volume":"147","author":"R Kramer","year":"2021","unstructured":"Kramer R, et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer. 2021;147:170\u201381.","journal-title":"Eur J Cancer"},{"issue":"2","key":"16117_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14740\/jh1090","volume":"12","author":"T Ohashi","year":"2023","unstructured":"Ohashi T, et al. Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis. J Hematol. 2023;12(2):66\u201374.","journal-title":"J Hematol"},{"issue":"24","key":"16117_CR20","doi-asserted-by":"publisher","first-page":"21666","DOI":"10.1002\/cam4.6724","volume":"12","author":"Y Tasaki","year":"2023","unstructured":"Tasaki Y, et al. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer Med. 2023;12(24):21666\u201379.","journal-title":"Cancer Med"},{"issue":"10","key":"16117_CR21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/iju.15220","volume":"30","author":"Y Tasaki","year":"2023","unstructured":"Tasaki Y, et al. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. Int J Urol. 2023;30(10):866\u201374.","journal-title":"Int J Urol"},{"key":"16117_CR22","doi-asserted-by":"publisher","first-page":"1117447","DOI":"10.3389\/fimmu.2023.1117447","volume":"14","author":"J Zhou","year":"2023","unstructured":"Zhou J, et al. Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis. Front Immunol. 2023;14:1117447.","journal-title":"Front Immunol"},{"issue":"7","key":"16117_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2022;21(7):495\u2013508.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"16117_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","volume":"96","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96(1):21\u201333.","journal-title":"Immunol Cell Biol"},{"issue":"25","key":"16117_CR25","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022;139(25):3594\u2013604.","journal-title":"Blood"},{"key":"16117_CR26","doi-asserted-by":"crossref","unstructured":"Martin M et al. Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database. Cancers (Basel). 2022;14(20).","DOI":"10.3390\/cancers14205030"},{"issue":"1","key":"16117_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s10637-019-00845-w","volume":"38","author":"S Refae","year":"2020","unstructured":"Refae S, et al. Germinal Immunogenetics predict treatment outcome for PD-1\/PD-L1 checkpoint inhibitors. Invest New Drugs. 2020;38(1):160\u201371.","journal-title":"Invest New Drugs"},{"key":"16117_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","volume":"130","author":"S Yano","year":"2020","unstructured":"Yano S, et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur J Cancer. 2020;130:198\u2013203.","journal-title":"Eur J Cancer"},{"issue":"1","key":"16117_CR29","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","volume":"7","author":"S Cook","year":"2024","unstructured":"Cook S, et al. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Netw Open. 2024;7(1):e2352302.","journal-title":"JAMA Netw Open"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16117-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16117-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:25:19Z","timestamp":1785749119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16117-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16117"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16117-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Institutional Review Board of the American University of Beirut (IRB approval number: BIO-2024-0295). The requirement for informed consent was waived due to the retrospective nature of the study. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"915"}}